​Publications

​

Weber WC, Streblow ZJ, Andoh TF, Denton M, Raué HP, Amanna IJ, Slifka DK, Kreklywich CN, Arduino I, Sulgey G, Streblow MM, Heise MT, Slifka MK, Streblow DN. Development of a virulent O'nyong'nyong challenge model to determine heterologous protection mediated by a hydrogen peroxide-inactivated chikungunya virus vaccine. PLoS Negl Trop Dis. 2025 Mar 17;19(3):e0012938. doi: 10.1371/journal.pntd.0012938. eCollection 2025 Mar. PMID: 40096126

 

Amanna IJ, Thomas A, Engelmann F, Hammarlund E, Raué HP, Bailey AL, Poore EA, Quintel BK, Lewis AD, Axthelm MK, Johnson AL, Colgin LMA, Diamond MS, Messaoudi I, Slifka MK.   Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model. Cell Rep Med. 2024 Jul 16;5(7):101655. doi: 10.1016/j.xcrm.2024.101655. PMID: 39019010

 

*Hendrickson SM, Thomas A, Raué HP, Prongay K, Haertel AJ, Rhoades NS, Slifka JF, Gao L, Quintel BK, Amanna IJ, Messaoudi I, Slifka MK. Campylobacter vaccination reduces diarrheal disease and infant growth stunting among rhesus macaques. Nat Commun. 2023 Jun 26;14(1):3806. doi: 10.1038/s41467-023-39433-1. PMID: 37365162.

*Chosen by the editors at Nature Communications as being among the 50 top papers in “microbiology and infectious diseases”

 

Slifka DK, Raué HP, Weber WC, Andoh TF, Kreklywich CN, DeFilippis VR, Streblow DN, Slifka MK, Amanna IJ. Development of a next-generation chikungunya virus vaccine based on the HydroVax platform. PLoS Pathog. 2022 Jul 5;18(7):e1010695. doi: 10.1371/journal.ppat.1010695. PMID: 35788221; PMCID: PMC9286250

 

Hendrickson SM, Thomas A, Prongay K, Haertel AJ, Garzel LM, Gill L, Barr T, Rhoades NS, Reader R, Galan M, Carroll JM, Roberts CT, Gao L, Amanna IJ, Messaoudi I, Slifka MK. Reduced infant rhesus macaque growth rates due to environmental enteric dysfunction and association with histopathology in the large intestine. Nat Commun. 2022 Jan 11;13(1):234. doi: 10.1038/s41467-021-27925-x. PMID: 35017515; PMCID: PMC8752659

 

Quintel BK, Prongay K, Lewis AD, Raué HP, Hendrickson S, Rhoades NS, Messaoudi I, Gao L, Slifka MK, Amanna IJ. Vaccine-mediated protection against Campylobacter-associated enteric disease.  Sci Adv. 2020 Jun 24;6(26):eaba4511. doi: 10.1126/sciadv.aba4511. eCollection 2020 Jun. PMID: 32637610; PMCID: PMC7314533

 

Slifka MK, Amanna IJ. Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses. Front Immunol. 2019 May 1;10:956. doi: 10.3389/fimmu.2019.00956. eCollection 2019. Review. PMID: 31118935. PMCID: PMC6504826

 

Woods CW, Sanchez AM, Swamy GK, McClain MT, Harrington L, Freeman D, Poore EA, Slifka DK, Poer DeRaad DE, Amanna IJ, Slifka MK, Cai S, Shahamatdar V, Wierzbicki MR, Amegashie C, Walter EB. An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults. Vaccine. 2019 Jul 9;37(30):4222-4230. doi: 10.1016/j.vaccine.2018.12.026. Epub 2019 Jan 18. PMID:30661836. PMCID: PMC6640644

 

Quintel BK, Thomas A, Poer DeRaad DE, Slifka MK, Amanna IJ. Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine. Vaccine. 2019 Jul 9;37(30):4214-4221. doi: 10.1016/j.vaccine.2018.12.020. Epub 2018 Dec 31. PMID: 30606462. PMCID: PMC6599721

 

Slifka MK and Amanna IJ. Dengue Serostatus and Dengue Vaccine Safety and Efficacy. N Engl J Med. 2018 Nov 15;379(20):1968. doi: 10.1056/NEJMc1811986. PMID: 30439281

 

Antia A, Ahmed H, Handel A, Carlson NE, Amanna IJ, Antia R, Slifka M. Heterogeneity and longevity of antibody memory to viruses and vaccines. PLoS Biol. 2018 Aug 10;16(8):e2006601. doi 10.1371/journal.pbio.2006601. PMID: 30096134. PMCID: PMC6105026

 

Amanna IJ and Slifka MK. Successful Vaccines. Curr Top Microbiol Immunol. 2018 Jul 26. doi: 10.1007/82_2018_102. PMID:30046984. PMCID: PMC6777997

 

**Slifka, MK and IJ Amanna (2018).  Chapter 8: Passive Immunization, in Plotkin’s Vaccines, 7th Edition, Eds. SA Plotkin, PA Offit, WA Orenstein, KM Edwards, Philadelphia, Elsevier.            

**This textbook won first prize in the Public Health category at the British Medical Association Awards

 

Poore EA, Slifka DK, Raué HP, Thomas A, Hammarlund E, Quintel BK, Torrey LL, Slifka AM, Richner JM, Dubois ME, Johnson LP, Diamond MS, Slifka MK, Amanna IJ (2017).  Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine. Vaccine. 2017 Jan 5;35(2):283-292. PMID: 27919629. PMCID: PMC5191926

 

Amanna IJ, Slifka MK (2016). Questions regarding the safety and duration of immunity following live yellow fever vaccination. Expert Rev Vaccines. 2016 Dec;15(12):1519-1533. Epub 2016 Jun 20. PMCID:  PMC5171234

 

Streblow DN, Hwee YK, Kreklywich CN, Andoh T, Denton M, Smith P, Hart E, Broekel R, Pallett C, Rogers K, Streblow AD, Chuop M, Perry A, Slifka M, Messaoudi I, Orloff SL (2015). Rat cytomegalovirus vaccine prevents accelerated chronic rejection in CMV-Naïve recipients of infected donor allograft hearts. Am J Transplant. Jul;15(7):1805-16. PMID: 25766876; PMCID: PMC5006870

 

Slifka MK (2014). Vaccine-mediated immunity against dengue and the potential for long-term protection against disease.  Front Immunol. May 6;5:195. PMID: 24834067 [PubMed] PMCID: PMC4018518

 

Slifka MK, Amanna I (2014).  How advances in immunology provide insight into improving vaccine efficacy. Vaccine. May 23;32(25):2948-57. PMID: 24709587. PMCID: PMC4096845

 

Amanna IJ, Slifka MK (2014). Current trends in West Nile virus vaccine development. Expert Rev Vaccines. May;13(5):589-608. PMID: 24689659. PMCID: PMC4279923

 

Slifka MK, Hammarlund E, Lewis MW, Poore EA, Hanifin JM, Marr KA, Hecox D, Amanna IJ. Antiviral Immune Response After Live Yellow Fever Vaccination of a Kidney Transplant Recipient Treated With IVIG. Transplantation. 2013 May 15;95(9)

 

Pinto AK, Richner JM, Poore EA, Patil PP, Amanna IJ, Slifka MK, Diamond MS. A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice. J Virol. 2013 Feb;87(4):1926-36.

 

Amanna IJ, Hammarlund E, Lewis MW, Slifka MK. Impact of infection or vaccination on pre-existing serological memory. Hum Immunol. 2012 Nov;73(11):1082-6.

 

Amanna IJ. Balancing the Efficacy and Safety of Vaccines in the Elderly. Open Longev Sci. 2012 Jun 29;6(2012):64-72.

​

Amanna IJ, Raué HP and Slifka MK (2012). Development of a new H2O2-based vaccine platform. Nat Med. Jun;18(6):974-9. PMID: 22635006. PMCID: PMC3506259